Format

Send to

Choose Destination
BMC Cancer. 2020 Feb 22;20(1):143. doi: 10.1186/s12885-020-6640-y.

miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.

Author information

1
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil.
2
Department of Breast and Reconstructive Surgery, Barretos Cancer Hospital, Barretos, SP, Brazil.
3
Department of Pathology, Barretos Cancer Hospital, Barretos, SP, Brazil.
4
Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, Braga, Portugal.
5
ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
6
Center of Molecular Diagnosis, Barretos Cancer Hospital, Barretos, SP, Brazil.
7
Department of Oncogenetics, Barretos Cancer Hospital, Barretos, SP, Brazil.
8
Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, SP, Brazil.
9
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil. mmcmsilveira@gmail.com.
10
Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, SP, Brazil. mmcmsilveira@gmail.com.
11
Tumor Biobank, Barretos Cancer Hospital, Barretos, SP, Brazil. mmcmsilveira@gmail.com.

Abstract

BACKGROUND:

MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene expression regulation and have been described as key regulators of carcinogenesis. Aberrant miRNA expression has been frequently reported in sporadic breast cancers, but few studies have focused on profiling hereditary breast cancers. In this study, we aimed to identify specific miRNA signatures in hereditary breast tumors and to compare with sporadic breast cancer and normal breast tissues.

METHODS:

Global miRNA expression profiling using NanoString technology was performed on 43 hereditary breast tumors (15 BRCA1, 14 BRCA2, and 14 BRCAX), 23 sporadic breast tumors and 8 normal breast tissues. These normal breast tissues derived from BRCA1- and BRCA2- mutation carriers (n = 5) and non-mutation carriers (n = 3). Subsequently, we performed receiver operating characteristic (ROC) curve analyses to evaluate the diagnostic performance of differentially expressed miRNAs. Putative target genes of each miRNAs considered as potential biomarkers were identified using miRDIP platform and used for pathway enrichment analysis.

RESULTS:

miRNA expression analyses identified several profiles that were specific to hereditary breast cancers. A total of 25 miRNAs were found to be differentially expressed (fold change: > 2.0 and p < 0.05) and considered as potential biomarkers (area under the curve > 0.75) in hereditary breast tumors compared to normal breast tissues, with an expressive upregulation among BRCAX cases. Furthermore, bioinformatic analysis revealed that these miRNAs shared target genes involved in ErbB, FoxO, and PI3K-Akt signaling pathways.

CONCLUSIONS:

Our results showed that miRNA expression profiling can differentiate hereditary from sporadic breast tumors and normal breast tissues. These miRNAs were remarkably deregulated in BRCAX hereditary breast cancers. Therefore, miRNA signatures can be used as potential novel diagnostic biomarkers for the prediction of BRCA1/2- germline mutations and may be useful for future clinical management.

KEYWORDS:

Biomarker; Hereditary breast tumors; NanoString; microRNA

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center